Natalie Smith
4 Papers
Natalie Smith is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has co-authored 2 publications.
Chat about Author
Papers
Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation.
Arielle Elkrief,Nicholas R. Waters,Natalie Smith,Angi Dai,John B. Slingerland,Nathan Aleynick,Binita Febles,Pooja Gogia,Nicholas D. Socci,Melissa Lumish,Paul A Giardina,Jamie E. Chaft,Juliana Eng,Robert J. Motzer,Robin B. Mendelsohn,Kate A. Markey,Mingqiang Zhuang,Yanyun Li,Zhifan Yang,Travis J. Hollmann,Charles M. Rudin,Marcel Van Den Brink,Jinru Shia,Susan DeWolf,Adam J. Schoenfeld,Matthew D. Hellmann,N. Esther Babady,David Faleck,Jonathan U. Peled +28 more
TL;DR: FMT was followed by clinical improvements in several cases of steroid- and biologic-agent-refractory irColitis, and was followed by clinical improvements in several cases of steroid- and biologic-agent-refractory irColitis.
6
Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis.
Arielle Elkrief,Natalie Smith,John B. Slingerland,Nathaniel Aleynick,Melissa Lumish,Paul A Giardina,Jamie E. Chaft,Paul B. Chapman,Juliana Eng,Robert J. Motzer,Robin B. Mendelsohn,Marcel R.M. van den Brink,Jinru Shia,Susan DeWolf,Matthew D. Hellmann,Jonathan U. Peled,David Faleck +16 more
TL;DR: In this paper , the authors used whole metagenomic shotgun sequencing (WMS) to profile the faecal microbiota profiles from N = 18 patients with immune-related colitis and described their clinical experience of N = 5 patients treated with healthy donor fecal microbial transplantation (FMT).
3
Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease.
Eiko Hayase,Tomoyoshi Hayase,Akash Mukherjee,Stuart Stinson,Mohamed A Jamal,Miriam Ortega,Christopher A. Sanchez,Saira Ahmed,Jennifer L. Karmouch,Chia-Chi Chang,Ivonne I Flores,Lauren K. McDaniel,Alexandria N. Brown,Rawan K. El-Himri,Valerie Chapa,Lin Tan,Bao Q. Tran,Yao Xiao,Christopher Fan,Dung T. Pham,Taylor Halsey,Yimei Jin,Wen Bin Tsai,Rishika Prasad,Israel Glover,Altai Enkhbayar,Aqsa Mohammed,Maren Schmiester,Katherine Y. King,Robert A Britton,Pavan Reddy,M. Wong,N. Ajami,J. Wargo,S. Shelburne,Pablo C. Okhuysen,Chen Liu,Stephanie W. Fowler,Margaret E. Conner,Zoe Katsamakis,Natalie Smith,Marina Burgos da Silva,Doris M. Ponce,Jonathan U. Peled,M. R. van den Brink,Christine Peterson,Gabriela Rondon,Jeffrey J. Molldrem,Richard E. Champlin,Elizabeth J. Shpall,Philip L. Lorenzi,Rohtesh S. Mehta,Eric C. Martens,Amin M. Alousi,Robert R. Jenq +54 more
Abstract: Acute lower gastrointestinal GVHD (aLGI-GVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation. Although the intestinal microbiota is associated with the incidence of aLGI-GVHD, how the intestinal microbiota impacts treatment responses in aLGI-GVHD has not been thoroughly studied. In a cohort of patients with aLGI-GVHD (n = 37), we found that non-response to standard therapy with corticosteroids was associated with prior treatment with carbapenem antibiotics and a disrupted fecal microbiome characterized by reduced abundances of Bacteroides ovatus. In a murine GVHD model aggravated by carbapenem antibiotics, introducing B. ovatus reduced GVHD severity and improved survival. These beneficial effects of Bacteroides ovatus were linked to its ability to metabolize dietary polysaccharides into monosaccharides, which suppressed the mucus-degrading capabilities of colonic mucus degraders such as Bacteroides thetaiotaomicron and Akkermansia muciniphila, thus reducing GVHD-related mortality. Collectively, these findings reveal the importance of microbiota in aLGI-GVHD and therapeutic potential of B. ovatus.